Komodo Health, the US-based healthcare analysis software provider that counts medical products distributor McKesson as an investor, secured $220m in series E funding yesterday at a reported $3.3bn valuation.
Hedge fund manager Tiger Global Management led the round, which also featured Casdin Capital, Iconiq Growth, Andreessen Horowitz and SVB Capital.
Founded in 2014, Komodo is the creator of a software platform that tracks the progress of patients’ treatment, using artificial intelligence and data science to identify ways to make the practice more efficient.
The round came just two months after the company raised $44m in a series D round led by Iconiq Growth and backed by McKesson’s corporate venturing subsidiary, McKesson Ventures, as well as Andreessen Horowitz, Oak HC/FT, IA Ventures and Felicis Ventures.
Andreessen Horowitz led Komodo’s $50m series C round in January 2020, investing alongside Oak HC/FT, IA Ventures and Felicis Ventures. It had previously received an undisclosed amount from McKesson Ventures, IA Ventures and Felicis Ventures in 2016.
Arif Nathoo, Komodo’s co-founder and chief executive, said: “This investment reaffirms our patient-centric approach to understanding every interaction with the healthcare system and building a flexible analytics platform based on that foundation.
“As digital adoption continues to accelerate rapidly and new sources of healthcare insights proliferate, Komodo enables the enterprise to address unmet needs of patients while reducing disparities in care.”
